Simulations Plus, Inc. (SLP)
| Market Cap | 300.46M |
| Revenue (ttm) | 80.54M |
| Net Income (ttm) | -62.79M |
| Shares Out | 20.21M |
| EPS (ttm) | -3.12 |
| PE Ratio | n/a |
| Forward PE | 35.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,060 |
| Open | 14.59 |
| Previous Close | 14.61 |
| Day's Range | 14.55 - 15.01 |
| 52-Week Range | 11.09 - 36.00 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 24.00 (+61.4%) |
| Earnings Date | Apr 9, 2026 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for SLP stock is "Buy." The 12-month stock price target is $24.0, which is an increase of 61.40% from the latest price.
News
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Earnings Call Transcript: Q2 2026
Revenue grew 8% to $24.3M in Q2, with strong software and services performance, improved gross margins, and robust cash reserves. AI integration and pharma collaborations are driving future growth, though management remains cautious due to macro risks.
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: TD Cowen 46th Annual Health Care Conference
The platform is expanding from point solutions to an integrated AI-enabled ecosystem, with a focus on cross-selling, value-based pricing, and deeper pharma engagement. FY 2026 growth is guided at 0%-4%, with stronger performance expected in the second half and significant AI-driven revenue upside anticipated in FY 2027.
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: AGM 2026
The meeting covered board elections, auditor ratification, an equity plan amendment, and executive compensation vote frequency. All proposals passed with strong support, and no shareholder questions were submitted during the Q&A.
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: Investor Day 2026
A unified, AI-enabled ecosystem is being developed to support the full drug development lifecycle, leveraging cloud, validated science, and integrated services. Fiscal 2026 guidance is reaffirmed, with new revenue streams and cross-selling expected to drive long-term growth and margin expansion.
Simulations Plus Earnings Call Transcript: Q1 2026
Revenue declined 3% to $18.4M, with strong services growth offsetting a 17% software drop. Gross margin improved to 59%, and guidance for FY26 remains unchanged, anticipating 0–4% revenue growth and a software mix of 57–62%.
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus Positioned to Capitalize on FDA's Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Stock Climbs On Earnings Strength, Biotech Market Rebound
Simulations Plus Inc. (NASDAQ: SLP) shares climbed on Tuesday after the company reported better-than-expected fourth-quarter 2025 earnings and reaffirmed annual guidance.
Simulations Plus Earnings Call Transcript: Q4 2025
Fiscal 2025 saw 13% revenue growth and strong adjusted EBITDA, despite Q4 declines and a $77.2M impairment. FY26 guidance projects flat to modest growth, with aggressive pricing and AI-driven product enhancements planned. Backlog and cash flow remain robust.
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in cheminformatics, biosimulation, clinical operations soluti...
SIMULATIONS PLUS INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Simulations Plus Investors to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Simulations Plus (SLP) To Contact Him Directly To Discuss Their Options If you purchased or...
SLP INVESTORS: Simulations Plus, Inc. Hit with Securities Fraud Investigation after Stock Plummets 26% -- Investors Urged to Contact BFA Law
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the ...
Simulations Plus Announces Preliminary Fiscal Year 2025 Results and Fiscal Year 2026 Guidance
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled perf...
SLP STOCK NOTICE: Simulations Plus, Inc. Investors with Losses may have been Affected by Securities Fraud – Contact BFA Law about its Pending Investigation
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Simulations Plus, Inc. (NASDAQ: SLP) for potential violations of the...